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P70S6KAcute myeloid leukemia (AML) is a deadly disease characterized by the clonal expansion and accumulation of
hematopoietic stem cells arrested at various stages of development. Clinical research efforts are currently
focusing on targeted therapies that induce apoptosis in AML cells. Herein, the effects and mechanisms of
the novel ﬂavone 3,3′-diamino-4′-methoxyﬂavone (DD1) on AML cell dysfunction were investigated in
AML cells (monoblast U937, myelomonocyte OCI-AML3, promyelocyte NB4, myeloblast HL-60) and blood
samples from patients with AML. The administration of DD1 inhibited proliferation and induced death of
AML cell lines and reduced the clonogenic activity of AML, but not normal, blood cells. The ﬂavone's apoptotic
action in U937 cells was associated with recruitment of mitochondria, Bax activation, Bad dephosphorylation (at
Ser136), activation of caspases -8, -9, and -3 and cleavage of the caspase substrate PARP-1. DD1 induced a marked
decrease in (i) Thr389-phosphorylation and (ii) protein levels of the caspase-3 substrate P70 ribosomal S6 kinase
(P70S6K, known for its ability to phosphorylate Bad). Caspase-dependent apoptosis and P70S6K degradation
were simultaneously prevented by the caspase inhibitors. Importantly, DD1 was shown to directly inhibit the
proteasome's chymotrypsin-like activity in U937 cells. Apoptotic activity of the proteasome inhibitor bortezomib
was also related to Bax activation and P70S6K downregulation. Accordingly, DD1 failed to induce P70S6K cleavage,
Bax stimulation and apoptosis in K562 cells resistant to bortezomib. These results indicate that DD1 has the poten-
tial to eradicate AML cells and support a critical role for Bax and P70S6K in DD1-mediated proteasome inhibition
and apoptosis of leukemia cells.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Acute myeloid leukemia (AML) is a clinically and genetically hetero-
geneous hematopoietic cancer characterized by the clonal expansion and
accumulation of immature myeloid precursors in the marrow and blood
[1,2]. Leukemia cells are unable to undergo growth arrest, terminal dif-
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l rights reserved.stimuli [1,2]. The conventional chemotherapeutic approach to treatment
of AML patients is based on a combination of an anthracycline with
cytarabine [1,2]. However, AML remains a challenging disease in the
clinic because patients are either refractory to front-line therapy or sub-
sequently relapse [2]. A range of drug candidates (including tyrosine
kinase inhibitors, farnesyltransferase inhibitors, histone deacetylase in-
hibitors and deoxyadenosine analogs) are now in clinical development
[1,2]. Other approaches are based on the identiﬁcation of compounds
capable of inducing apoptosis, which is impaired in AML cells.
A survey of the literature of natural compounds indicates that
polyphenols [3] such as ﬂavonoids [4,5] and isoﬂavones [4,6] have
antitumor activity. In molecular terms, these compounds downregulate
the expression of anti-apoptotic proteins and inhibit major signaling
pathways (PI3K/Akt, NF-κB and MAPK) and proteasome activity [3,7–9].
The ﬂavonoids quercetin and ﬂavopiridol have been shown to induce ap-
optosis caspase-dependent and -independent mitochondrial cell death
pathways [10,11]. Quercetin promotes tumor-selective apoptosis through
downregulation of Mcl-1 and activation of Bax [11], whereas the lethal
1317M. Piedfer et al. / Biochimica et Biophysica Acta 1833 (2013) 1316–1328effects of ﬂavopiridol proceed through multiple targets including cyclin-
dependent kinase inhibition, downregulation of Mcl-1 and XIAP, and in-
terference with the PI3K/AKT and TNF cell signaling pathways [12,13].
Flavopiridol is now being evaluated in Phase I clinical trials in poor-risk
and relapsed/refractory AML [14,15]. Modest antileukemic activity has
been observed, although most patients experience side effects such as
short-duration neutropenia, diarrhea, cytokine release syndrome and
fatigue [14,15]. Novel, less toxic pro-apoptotic compounds are thus
required.
Our group previously reported on the synthesis and biological
properties of ﬂavones [16,17] that selectively inhibit the tumor-
associated aminopeptidase-N/CD13 in AML cells [17]. The com-
pound 2′, 3-dinitroﬂavone-8-acetic acid (DNFAA; Fig. 1) proved
to be the most efﬁcient inhibitor of APN/CD13 [17,18]. A second
ﬂavone belonging to this family, 3,3′-diamino-4′-methoxyﬂavone
(DD1; Fig. 1), was shown to induce apoptosis of primary chronic
lymphocytic leukemia cells [19].
In the present study, we sought to determine whether the ﬂavone
DD1 has potential drug activity in AML disease through the inhibition
of growth and survival processes. We compared the effects of DD1 to
that of DNFAA. Our results demonstrated that treatment with DD1
triggers apoptosis of AML cells. The underlying mechanisms and in-
tracellular signaling pathways affected by DD1 were investigated.
We found that DD1, as a novel proteasome inhibitor, targets Bax acti-
vation and P70S6K degradation during AML apoptosis.
2. Materials and methods
2.1. Chemicals and reagents
The 3-aminoﬂavones DD1 and DNFAA (Fig. 1) were synthesized as
described in [16,17] respectively, and stock solutions (100 mM) in
DMSOwere prepared. Flavopiridol (prepared as a 10 mMstock solution
in DMSO) was donated by Aventis Pharmaceuticals (Bridgewater, NJ,
USA). Bortezomib (100 mM stock solution prepared in DMSO)
was from Millennium Pharmaceuticals Inc. (Cambridge, MA, USA).
Anti-phospho-Ser136-Bad (Ser136, rabbit IgG), anti-Bad (H-168,
rabbit IgG), anti-PARP-1 (F-2, mIgG2a), anti-Bax speciﬁc for the activeO
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Fig. 1. Chemical structures of DNFAA and DD1. DD1: 3,3′-diamino-4′-methoxyﬂavone;
C16H14N2O3; 282.3 g/mol. DNFAA: 2′, 3-dinitroﬂavone-8-acetic acid; C17H10N2O8;
370.27 g/mol. Both compounds were stored frozen in DMSO.form (6A7, mouse IgG), anti-Bid (FL-195, rabbit IgG), anti-Bcl-2 (100,
mouse IgG1) and anti-Mcl-1 (S-19, rabbit IgG) antibodies were from
Santa-Cruz (Tebu-Bio SA, Le Perray en Yvelines, France). Anti-Akt1
(H-136, rabbit IgG), anti-phospho-Ser473-Akt1 (104A282, mouse IgG1),
anti-phospho-Thr389-P70S6K (Thr389, rabbit IgG) and anti-P70S6K
(rabbit IgG) antibodies were from Cell Signaling Technology Inc. (New
England Biolabs, Hitchin, UK). Anti-actin (C4,mIgG1)was from ICN Bio-
medicals (Aurora, OH, USA). Anti-Noxa (6D619, mIgG1) was from US
Biologicals/Euromedex (Mundolsheim, France). Anti-Bax (speciﬁc for
the total protein) (33–6400, mIgG1) was obtained from Zymed Labora-
tories (San Francisco, CA, USA). Secondary antibodies were horseradish
peroxidase-conjugated antibodies from Dako Cytomation (Glostrup,
Denmark). ZIETD-fmk (a caspase-8 inhibitor), zVAD-fmk (a general
caspase inhibitor), caspase-3/8/9 assay kits, recombinant human (rh)
SCF, rhGM-CSF, rhIL-3 andmethylcellulose-basedmedia were obtained
from R&D Systems (Abingdon, UK). Anti-Bak speciﬁc for the active form
(TC-100, mouse IgG2A) and zDEVD-fmk (a caspase-3 inhibitor) were
from Calbiochem (Darmstadt, Germany). Ac-LEHD-CHO (a caspase-9
inhibitor) was from AG Scientiﬁc, Inc. (San Diego, CA, USA). The
proteasome-Glo™ chymotrypsin-like cell-based assay was obtained
from Promega-France (Charbonnières-les-Bains, France).
2.2. Patient samples
Leukemic blood samples from 12 treatment-naive AML patients (age
range: 25–80)were obtained from the “TumorothèqueHématologie” bi-
ological resource center at Saint-Antoine Hospital (Paris, France) after
the provision of written, informed consent (formulary EORTC study
#06012). The diagnosis of AMLwas established in accordancewith stan-
dard clinical criteria and the FAB Committee's cytological criteria (≥80%
peripheral blood CD33+ AML blasts). The study was conducted and
monitored in compliance with the Declaration of Helsinki 2002.
Ethics approval was given by the independent ethics committees
at Saint-Antoine Hospital (Paris, France) and the French National Insti-
tute of Cancer (“Tumorothèque Hématologie” Paris-Saint-Antoine Hos-
pital COHO0203 INCA 2007). Control blood samples from healthy, fully
anonymized donors were purchased from the Etablissement Français
du Sang (Hôtel-Dieu Hospital, Paris, France) and required no special
written informed consent. Peripheral blood mononuclear cells (PBMCs)
were separated by Ficoll–Hypaque density gradient (1.077 g/ml)
centrifugation. Cells (106/ml) were cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gibco;
LPS levels b 0.1 ng/ml), 2 mM L-glutamine, 1 mM sodium pyruvate
and 40 μg/ml gentamycin (Gibco) in a 5% CO2 humidiﬁed atmosphere
at 37 °C.
2.3. Cell lines
The AML cell lines U937 (ATCC CRL-1593.2; French-American-British/
FAB phenotype M5 monoblast), OCI-AML3 (M4, myelomonocyte) [20],
NB4 (M3, promyelocyte) [21] and HL-60 (ATCC CCL-240; M2, myelo-
blast), and the chronic myeloid leukemia/CML cell line K562 (ATCC
CCL-243) were cultured in complete RPMI 1640 medium supplemented
with 5% FCS in a 5%CO2 humidiﬁed atmosphere at 37 °C. The T acute lym-
phoid leukemia/T-ALL cell line Jurkat (ATCC TIB-152), the B chronic lym-
phoid leukemia/CLL cell line MEC-1 (DSMZ ACC497) and the myeloma
cell line U266 (ATCC TIB-196) were cultured in complete RPMI 1640
medium supplemented with 10% FCS. The epithelial tumor cell lines
used were HeLa (ATCC CCL-2™, cervix adenocarcinoma) and COLO
205 (ATCC CCL-222™, colorectal adenocarcinoma). COLO 205 was cul-
tured in complete RPMI 1640with 5% FCS. HeLawas cultured in complete
DMEM-F12 with 10% FCS. For every experiment, cells were harvested in
log-phase proliferation at passage 12 or less. Cells (1–3 × 105/ml) were
treated with various concentrations (1–100 μM) of DD1 or DNFAA for
various periods of time. Flavopiridol (0.1 μM)was used as a positive con-
trol for apoptosis induction. In negative control experiments, cells were
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DNFAA in the corresponding experiments. In caspase experiments, inhib-
itors were added 60 min prior to the addition of DD1.
2.4. Cell viability and proliferation and cell cycle phase distribution
analysis
The proliferation of cell lines was evaluated by counting the num-
ber of viable cells (with diameters ranging from 9 to 14 μm) and dead
cells (diameters ranging from 4 to 9 μm) in a Coulter Multisizer
(Beckman-Coulter, Villepinte, France). Cell cycle status was deter-
mined as described in [22] with a ﬂow cytometer (Beckman-Coulter,
Villepinte, France).
2.5. Colony formation/survival assay
The leukemic colony-forming cells (L-CFC) possess self-renewal
potential and the capacity to undergo at least limited, although abnor-
mal, differentiation to non proliferating cells [23]. For normal peripheral
blood cells (PBMCs), the progenitors give rise to granulocytes and
monocyte/macrophage cells [24,25]. Normal PBMC or primary
AML cells were seeded (105/ml) in methylcellulose-based media
supplemented with FCS (25%), bovine serum albumin (2%), L-glutamine
(2 mM), 2-mercaptoethanol (5 × 10−5 M), rhSCF (50 ng/ml), rhGM-
CSF (10 ng/ml) and rhIL-3 (10 ng/ml). GM-CSF, IL-3 and SCF are
promoters of L-CFC growth and IL-6 is a costimulator to augment
clonogenicity of AML blasts [23–26]. DD1 (20 μM) was added at
the initiation of the cultures. The cultureswere incubated in 35 mm tis-
sue culture dishes in triplicate for 14 days in a 5% CO2 humidiﬁed atmo-
sphere at 37 °C. The number of colonies deﬁned as clusters of≥50 cells
were counted by inverted light microscopy on day 14 of culture.
2.6. Detection of apoptosis by ﬂow cytometry
Apoptosis was measured using the annexin-V-FITC/PI apoptosis
detection kit (Beckman-Coulter). Stained cells (40,000) (AML cell
lines and primary blasts) were analyzed using a ﬂow cytometer
(Beckman-Coulter). Values are quoted as the percentage of positive
cells. The results from the cell apoptosis assay were analyzed by
the use of CalcuSyn software (version 2, Biosoft, Cambridge, UK),
which was used to calculate the combination index (CI) to determine
the presence of antagonism, additivity or synergism between drug-
treatment groups. Values b 0.9 indicate synergy, values between 0.9
and 1.1 indicate additive effects, and values > 1.1 indicate antagonistic
interactions.
2.7. DNA fragmentation assay
Cells were washed twice with PBS and lysed in M-PER buffer
(ThermoFisher Scientiﬁc, Ilkirch, France) for 60 min on ice. Lysates
containing fragmented DNA were cleared by centrifugation at 10,000 g
for 15 min. Supernatant samples were treated with proteinase K
(500 μg/ml) at 50 °C for 2 h. Thereafter, RNAse A (500 μg/ml) was
added and the sampleswere incubated at 50 °C for 90 min. Electropho-
resis was performed in 1.8% agarose gels containing ethidium bromide.
The gel bands were analyzed in a densitometer (Appligène-Oncor SA,
Illkirch, France).
2.8. The mitochondrial membrane potential assay
The loss of mitochondrial membrane potential was analyzed using
the mitochondrial detection kit (Biomol GmbH, Hamburg, Germany),
as described previously [27]. Following drug treatment, cells were la-
beled with the lipophilic ﬂuorochrome JC-1. The sample's ﬂuorescence
was recorded in aWallac Victor 2 multitask plate reader (Perkin Elmer,
Norwalk, MT, USA). Depolarization of the mitochondrial membrane ischaracterized by a shift from red ﬂuorescence (FL2) to green ﬂuores-
cence (FL1), i.e. a reduction in the red/green ﬂuorescence ratio.
2.9. Caspase assays
Caspase-3, -8 and -9 activities in cell lysates (100 μg/assay) were
assayed with speciﬁc substrates (DEVD-pNA, IETD-pNA and LEHD-pNA,
respectively) using the caspase cellular activity assay kits (R&DSystems),
according to the manufacturer's instructions. Formation of pNA was
monitored at 405 nm. Comparison of the absorbance of pNA from a
treated sample with that from a control sample yields the relative in-
crease in caspase activity. Experiments were performed in duplicate
(at least).
2.10. The proteasome chymotrypsin-like activity assay
Proteasome chymotrypsin-like activity was assayed with the speciﬁc
substrate N-succinyl-Leu-Leu-Val-Tyr-aminoluciferin (Suc-LLVY-AL) and
cells (5 × 104/assay) using the chymotrypsin-like cellular activity assay
kit (Promega) according to the manufacturer's instructions. Released
luciferin serves as a substrate for luciferase in a simultaneous light-
generating reaction. Luminescence was measured with a Wallac
Victor-2 spectrophotometric microplate reader. Comparison of the
luminescence from a treated sample with that from a control sample
yielded the relative inhibition of chymotrypsin-like activity. Experiments
were performed in duplicate (at least).
2.11. Immunoblotting
Cells were lysed inM-PER buffer (Pierce Biotechnology, Rockford, IL,
USA) supplemented with protease and phosphatase inhibitor cocktails
(Sigma). Total cell extracts were separated on 12% SDS-PAGE, trans-
ferred to nitrocellulose and blotted as described previously [28]. Immu-
noblottingwas performedwith primary antibodies diluted according to
the manufacturer's instructions and samples were then incubated with
HRP-coupled secondary antibodies. Blots were visualized with an en-
hanced chemiluminescence kit (GE Healthcare Europe, Saclay, France).
2.12. Statistics
Data are presented as the mean ± SD from N independent exper-
iments. A two-tailed, paired Student's t-test was used to compare test
and control groups. The threshold for statistical signiﬁcance was set
to P b 0.05.
3. Results
3.1. Flavone DD1 inhibits proliferation and induces apoptosis in AML cells
We ﬁrst examined the effects of DD1 on the growth and viability
of monoblastic U937 cells. Cells were cultured for various periods of
time (24, 48, 72 and 96 h) in the presence of a range of concentrations
(2–20 μM) of DD1 orwith vehicle (DMSO). Cell proliferationwasmark-
edly reduced in DD1-treated samples, when compared with vehicle or
no treatment (Fig. 2A). The ﬂavone DNFAA did not affect the prolifera-
tion of U937 cells after 96 h of treatment at 20 μM (Fig. 2A). Kinetic
studies revealed a dose- and time-dependent inhibitory effect of DD1
on U937 cell proliferation (Fig. 2A). Inhibition of cell proliferation was
accompanied by a transient, time-dependent accumulation of cells in
the G2/M phase and then a reduction in DNA content to sub-G1 levels
(Fig. 2B), and by the DNA fragmentation (Fig. 2C) that are characteristic
of apoptosis. A positive controlwith ﬂavopiridol [29] induced DNA frag-
mentation to a similar extent, whereas DNFAA did not have any effect
(Fig. 2C). Apoptosis was further conﬁrmed by phosphatidylserine expo-
sure at the cell surface, as evidenced bymarked annexin-V-FITC binding.
Necrotic cells were also detected by propidium iodide (PI) staining.
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Fig. 2. DD1 blocks proliferation and induces apoptosis in U937 cells. (A) U937 cells (105/ml) were treated with DD1 at the indicated concentrations (2–20 μM) and for the indicated
times. Controls included DNFAA 20 μM and vehicle (DMSO). Cell proliferation (quantiﬁed as the percentage of untreated cells) was measured by direct cell counting. Data are quoted as the
mean ± SD from at least three independent experiments, each performed in triplicate. (B) The DNA content of U937 cells treated for 24 or 48 h with DD1 (10 μM)was analyzed by ﬂow cy-
tometry. (C, D) U937 cells were cultured for 72 h in the presence or absence of 10 μMDD1, 10 μMDNFAA or 0.1 μM ﬂavopiridol (a positive control for apoptosis in U937 cells). (C) DNA frag-
mentation; (D) detection of apoptotic cells after annexin-V-FITC/PI staining and ﬂow cytometry. Results are expressed as log PI ﬂuorescence intensity (y-axis) vs. log annexin-V-FITC
ﬂuorescence intensity (x-axis). L1: necrotic cells; L2: apoptotic + secondary necrotic cells; L3: apoptotic cells. (E, F) U937 cells were treated with 10 μM DD1 or DNFAA for the indicated
times (E) or treated with the indicated concentrations for 40 h (F). The percentage of apoptotic cells was determined as in (D) (L2 + L3 gates). Data are quoted as the mean ± SD from
four independent experiments. P b 0.01 compared with untreated cells.
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ﬂavopiridol-treated cells than in untreated cells or DNFAA-treated cells
(Fig. 2D). The DD1 pro-apoptotic effect was both time- (Fig. 2E) and
dose-dependent (Fig. 2F). The other AML cell lines HL-60 (myeloblastic),
NB4 (promyelocytic) and OCI-AML3 (myelomonocytic) were also found
to be sensitive to the inhibitory effects of DD1 (Fig. 3A). Since primary
blasts from AML patients do not proliferate under short-term culture
conditions,we therefore examined the effect of DD1 on the clonogenicity
of AML blasts and normal blood cells by culturing cells inmethylcellulose
and growth factors to maintain cell proliferation and survival. DD1 did
not affect the colony formation of normal blood cells (Fig. 3B). In contrast,
DD1 (20 μM) inhibited colony formation/survival of samples from AML
patients (Fig. 3C and D). There was no correlation between the FAB
subtype and the response of leukemia cells to DD1 (Fig. 3C and D). As
exempliﬁed in Fig. 3E, the optimal effects of DD1 in inducing apoptosis
of responding AML cells in liquid culture was observed at 96 h with
20 μM DD1. In contrast, DD1 did not markedly affect the viability ofnormal PBMCs (Fig. 3E). In further experiments, we investigated themo-
lecular mechanisms underlying the pro-apoptotic effect of DD1 on U937
cells (using DNFAA as a negative control).
3.2. DD1-induced apoptosis is caspase-dependent
Caspases -3, -8 and -9 are importantmediators of apoptosis; caspases
-8 and -9 are initiator caspases, and caspase-3 is the “executioner
enzyme” [30]. In parallel, we studied the ability of U937 cell lysates to
cleave chromogenic substrates of caspase-3, caspase-8 and caspase-9.
UntreatedU937 cells displaydetectable baseline levels of all three caspase
activities (Fig. 4A) and the broad-spectrum caspase inhibitor zVAD-fmk
inhibited caspase activities (data not shown). Cell treatment with DD1
for 24 h resulted in a maximal increase in all three caspase activities,
relative to untreated cells or DNFAA-treated cells (Fig. 4A). Flavopiridol
(0.1 μM) was used as a positive control [10], since it is known to trigger
U937 cell death by activating all three caspases studied here (Fig. 4A).
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Fig. 3. DD1 induces apoptosis in AML cell lines and inhibits colony formation capacity of blood cells from patients with AML. (A) AML cell lines were treated with DD1 (20 μM) for
72 h. Cell proliferation was measured as in Fig. 2A and apoptosis as in Fig. 2D. Data are quoted as the mean ± SD from three independent experiments. The baseline apoptosis value was
subtracted from the DD1-mediated apoptosis value. (B, C, D) Blood cells (106/ml) from normal donors (n = 2) (B) and AML patients (n = 12) (C, D) were grown in methylcellulose in the
presence or absence of DD1 (20 μM) for 14 days. AML blast cells were characterized according to the French American British (FAB) M0 (undifferentiated), M1 (myeloblast), M2 (myeloblast
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number of colonies. (B, C) ≤ 100 colonies and (D) ≥ 100 colonies in untreated samples. The asterisks indicate a statistically signiﬁcant difference (*P ≤ 0.05; **P ≤ 0.006). (E) Normal or AML
cells were cultured in suspension for 96 h in the presence or absence of DD1 (20 μM) for 4 days and apoptosis was assessed as described in Fig. 2D. Annexin-V-positive cells are highlighted in
the box and their percentage is shown in the ﬁgure. Representative experiments are shown.
1320 M. Piedfer et al. / Biochimica et Biophysica Acta 1833 (2013) 1316–1328Accordingly, Western blot analysis showed that exposure of U937 cells
to increasing concentrations of DD1 induced the cleavage of the down-
stream caspase-3 substrate PARP-1 (Fig. 4B). To determine whether acti-
vated caspases are involved in DD1's apoptotic action, we examined the
effects of caspase inhibitors on cell apoptosis (as determined byannexin-V-FITC binding). DD1-mediated apoptosis was strongly blocked
by 50 μM zVAD-fmk (Fig. 4C), zDEVD-fmk (caspase-3 inhibitor) as well
as zIETD-fmk (caspase-8 inhibitor) and AcLEHD-CHO (caspase-9 inhibi-
tor) (data not shown). Overall, these results strongly suggested that
DD1 at least induces caspase-dependent apoptosis through the
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Fig. 4. DD1-induced apoptosis in U937 cells is caspase-dependent. (A) U937 cells were treated for 24 h with 10 μM DD1 or left untreated. Controls include treatment for 24 h with
10 μM DNFAA or 0.1 μM ﬂavopiridol. Caspases -8, -9 and -3 activities were respectively determined using the speciﬁc substrates IETD-pNA, LEHD-pNA and DEVD-pNA. The release
of pNA was measured at 405 nm. The data are expressed as pmol pNA/60 min/μg protein. Data are the mean ± SD from three determinations. (B) Lysates from U937 cells treated
for 24 h with DD1 (5–20 μM) or DNFAA (10 μM) were assayed for PARP-1 expression by immunoblotting. The cleaved form of PARP-1 has a molecular weight of 89 kDa. (C) U937
cells were incubated with 20 μM DD1 for 24 h after a 1 h pretreatment with 50 μM zVAD-fmk (a broad-spectrum caspase inhibitor). The percentage of apoptotic cells was deter-
mined after annexin-V-FITC/PI staining and ﬂow cytometry (L2 + L3 gates).
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pathways.3.3. DD1 induces mitochondrial membrane depolarization, Bax upregulation
and Bad dephosphorylation
To conﬁrm the intrinsic pathway's involvement in DD1-induced apo-
ptosis, we investigated the status of the mitochondria. In a ﬂuorescence-
based assay, exposure of U937 cells to DD1 (10 and 20 μM) for 48 h
induced a marked decrease in the mitochondrial membrane potential,
when compared with DNFAA or the absence of treatment (Fig. 5A). Mi-
tochondrial membrane depolarization can result from the action of
pro-apoptotic and/or anti-apoptotic members of the Bcl-2 family [30].
In particular, the arrangement of the pro-apoptotic proteins Bax and
Bak in mitochondrial membrane-bound complexes plays a critical role
in permeabilizing the mitochondrial outer membrane [31]. Untreated
U937 cells expressed high levels of Bcl-2 and Mcl-1 anti-apoptotic pro-
teins (Fig. 5B) and Bak (active form) and Noxa pro-apoptotic proteins
(Fig. 5C). After 40 h of cell culture with 5–20 μM DD1, no changes in
the levels of these proteins (when normalized against actin levels) were
observed (Fig. 5B,C). Bid is a known caspase substrate and the production
of truncated Bid (tBid) can activate the intrinsic pathway of apoptosis
[32]. UntreatedU937 cells expressedhigh levels of Bid andDD1 treatment
did not lead to either loss of intact Bid (Fig. 5C) or formation of tBidfragments (14–15 kDa) (data not shown). In contrast, untreated
U937 cells expressed very low baseline levels of the active form of
Bax pro-apoptotic protein when compared to total Bax (Fig. 5D, E).
DD1markedly induced the active form of Bax in a dose-dependentman-
ner after 20 and40 hof culture (Fig. 5D, E)whereas the levels of total Bax
remained unchanged (Fig. 5E). Dephosphorylation of Bad protein on
Ser136 induces apoptosis in AML cells [33]. Here, U937 cells were
negative for Ser112-phospho(p)-Bad (data not shown) and positive
for Ser136-p-Bad (Fig. 5D, E). A marked time- and dose-dependent
decrease in the level of Ser136-p-Bad was seen in response to DD1,
whereas there was no change in the levels of total Bad (Fig. 5D, E).3.4. The p70S6 kinase degradation and Bax stimulation induced by DD1
are related to apoptosis
Bad is a downstream target of kinase Akt1 [34] and p70S6 kinase
(P70S6K, a downstream effector of mTOR) [35]. Akt1 can be fully
activated by phosphorylation at Ser473 by PDK2; whereas activation
of P70S6K1 requires phosphorylation at Thr389 by mTOR [36]. We
therefore looked at whether DD1 might inhibit the activity of these
kinases. Hence, we measured the respective levels of Ser473-p-Akt1
and Thr389-p-P70S6K in U937 cells before and after DD1 treatment. The
levels of Ser473-p-Akt1 and Akt1 proteins were similar in DD1-treated,
DNFAA-treated and untreated U937 cells (Fig. 6A). In contrast, the
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DD1-treated cells than in DNFAA-treated and untreated cells (Fig. 6B).
A recent study demonstrated that P70S6K is speciﬁcally cleaved by
caspase- 3 [37]. This report prompted us to determine whether or not
downregulation of P70S6K by DD1 was due to proteolytic cleavage of
the full-length-protein. As seen in Fig. 6C and D, zVAD-fmk and the
caspase-3 inhibitor zDEVD-fmk blocked the cleavage of P70S6K by
DD1. The caspase-9 and -8 inhibitors (AcLEHD-CHO and zIETD-fmk)were also capable of inhibiting cleavage (Fig. 6E, F), this can be explained
by the fact that caspase- 8 and caspase-9 activation results in the subse-
quent activation of caspase-3. In parallel, the levels of active Baxwere not
affected by cell treatment with the caspase inhibitors (Fig. 6C–F). Taken
as a whole, these data demonstrate that caspase inhibitors that block
DD1-mediated apoptosis also block P70S6K degradation.
We next looked at whether P70S6K degradation was directly in-
volved in DD1-mediated apoptosis. To this end, we chose to study the
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Cell proliferation was reduced in DD1-treated samples (when compared
with the absence of treatment) (data not shown). However, ﬂow cytom-
etry showed that DD1 (at 20 μM) induced necrosis (as detected by PI
staining) rather than apoptosis (Fig. 6G). The K562 cells expressed de-
tectable levels of P70S6K and no changes were observed when cells
were treated with DD1 (Fig. 6H). Moreover, the levels of active Bax pro-
tein were not affected by 5–20 μM DD1, when normalized against actin
levels (Fig. 6H). These results showed that P70S6K was not degraded
and active Bax was not induced by DD1 in apoptosis-resistant K562
cells. This observation therefore argues in favor of the involvement of ac-
tive Bax and P70S6K in DD1-mediated apoptosis in U937 cells.3.5. DD1's inhibitory effect on proteasome activity in U937 cells
The observed association between Bax accumulation and apoptosis
prompted us to investigate the relationship between DD1-mediated ap-
optosis and proteasome inhibition. First, we showed that chymotrypsin-
like activity was signiﬁcantly lower in U937 cells treated for 40 h with
2–20 μM DD1 than in untreated cells or cells treated with DNFAA or
ﬂavopiridol (Fig. 7A). We then looked at whether DD1 might directly
inhibit chymotrypsin-like activity in vitro. The proteasome inhibitor
bortezomib was also assayed as a positive control; as expected, it
strongly suppressed chymotrypsin-like activity (Fig. 7B). Surpris-
ingly, DD1 also produced effective and immediate inhibition of
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2 μM (Fig. 7B). Western blot proﬁles in bortezomib-treated U937
cells revealed that bortezomib, like DD1, had strikingly similar effects on
active Bax induction and p70S6K downregulation (Fig. 7C). Flow cytome-
try showed that bortezomib induced dose-dependent apoptosis in U937
cells (IC50 around 10 nM at 18h) and apoptosis was strongly blocked byD
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a combination of DD1 (1–10 μM) and bortezomib at suboptimal dose
(5 nM) led to a more pronounced apoptotic response in U937 cells,
when compared with each compound alone (Fig. 7D). As assessed by
CalcuSyn (Fig. 7D), the bortezomib/DD1 combination produced additive
interactions (CI values 0.9–1.1 at 2, 5 and 10 μM of DD1). These resultsB
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he mean ± SD from three determinations. (B) Chymotrypsin-like activity was assayed
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antibodies against P70S6K and Bax. (D) U937 cells were cultured for 20 h with DD1
M) or buffer. Detection of apoptotic cells after annexin-V-FITC/PI staining and ﬂow cy-
ezomib was determined by combination index (CI) and by the fractional effect analysis
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degradation is amarker of proteasome inhibition byDD1and bortezomib.
3.6. Effects of DD1 toward other tumor cell models
We assessed here the impact of DD1 on other cell lines representa-
tive of hematological and solid malignancies whose characteristics are
reported in Table 1. Cells were incubated 48 h either in the absence or
in the presence of increasing concentrations of DD1 (1–100 μM) and
the effects of DD1 on the growth and viability of were measured. With
regard to hematological cells, the anti-proliferative and cytotoxic effects
of DD1 were more pronounced on the AML cell lines and the T-ALL
Jurkat cells than on the myeloma U266 and B-CLL MEC-1 cell lines
(Table 1). Accordingly, our previous studies showed that DD1 induced
the apoptosis of the leukemia B cell lines Eskol and WSU-CLL, and of
B-CLL patients' cells ex vivo with an IC50 ≥ 50 μM [19]. DD1 also in-
duced a dose-dependent growth arrest in the CML K562 cells but this
was not associated with apoptosis as shown before (Table 1). Within
the epithelial cell compartment, the HeLa cells appeared to be more
sensitive to DD1 compared with the COLO205 cells (Table 1).
4. Discussion
This study reported on the novel ﬂavone DD1's pro-apoptotic prop-
erties in human AML cell lines and blasts from patients with AML. We
demonstrated for the ﬁrst time that this drug simultaneously inhibits
two signaling pathways which are of importance for AML cell survival
i.e. the proteasome and mTOR signalings, associated with caspase acti-
vation and P70S6K degradation.
DD1 promoted apoptosis of U937 cells while DNFAA, with a back-
bone structurally similar to DD1, did not affect U937 cell survival, thus
suggesting that substitutions with amine and methoxy groups in DD1
are important for conferring its pro-apoptotic activity. DD1 also exhibited
pro-apoptotic properties in AML cell lines of distinct phenotypes, HL-60,
NB4 and OCI/AML3. Moreover, the blast colony-forming potential
of AML samples, but not normal blood cells, was inhibited by DD1,
supporting the critical role of DD1 in leukemia cell death. The p53
tumor suppressor has a pivotal role in the response to DNA damage
and the determination of whether cells undergo cell cycle arrest or
apoptosis [39]. The NB4 and OCI/AML3 cells express p53, whereas
HL-60 and U937 cells do not. All these cell lines are sensitive to the
inhibitory activity of DD1 thus indicating that DD1-mediated apo-
ptosis in AML cells is p53-independent.
We analyzed the modulation of the signaling pathways underly-
ing DD1-induced apoptosis. The PI3K/Akt/mTOR signaling pathwayTable 1
DD1 effects on hematological and epithelial malignancies.
Tumor entity Human cell line Growth
arrest
IC50 (μM)
Death
induction
IC50 (μM)
AML NB4, U937, HL-60, OCI AML3 10–20 10–20
CML K562 5 –
T-ALL Jurkat 10 10
B-CLL MEC-1 >50 >50
Myeloma U266 50 50
Cervix adenocarcinoma HeLa 20 50
Colorectal adenocarcinoma COLO 205 Resistanta –
Cells (2 × 105/ml) and were treated for 48 h with various concentrations of DD1
(1–100 μM) or treated with equivalent concentrations of DMSO (vehicle). Cell growth
and death (quantiﬁed as the percentage of untreated cells) were measured by direct
cell counting as detailed in the Materials and methods. Moreover, morphological ob-
servations showed the appearance of apoptotic bodies under microscopic observation
in DD1-treated cells (apart K562 and COLO205). Apoptotic cells were also detected
after annexin-V-FITC/PI staining and ﬂow cytometry. Data are quoted as the mean
from two independent experiments. Results are expressed as IC50 values determined
for each cell line.
a Treatment of COLO205 cells with 100 μM DD1 resulted in ≤20% growth arrest.regulating cell proliferation and survival is frequently found to be ac-
tivated in AML [40]. Full activation of Akt1 involves phosphorylation
on Thr308 and Ser473 residues [41]. The activation of mTOR by PI3K/Akt
involves a direct Akt-mediated phosphorylation of mTOR [42]. The latter
is involved in the control of cell proliferation, translation initiation and
cell cycle progression by phosphorylating proteins from the 4EBP1 fam-
ily and S6 protein kinases including P70S6K [43,44]. P70S6K (a down-
stream effector of mTOR) has been linked to a wide range of cellular
processes, including protein synthesis, mRNA processing, cell prolifera-
tion and cell survival [44]. Our Western blot experiments indicated that
although DD1 did not affect the phosphorylation status of Akt1, it mark-
edly decreased the level of P70S6K phosphorylation. Interestingly, the
DD1-induced decrease in P70S6K phosphorylation was correlated with
downregulation of P70S6K protein expression. This observation indi-
cates that DD1-induced apoptosis interferes with Akt pathway signaling
downstream of Akt1 and mTOR.
The Bcl-2 family member Bad is a direct downstream target for
P70S6K [35]. Ser136-phosphorylation of Bad protects AML cells from
apoptosis [45] whereas dephosphorylated Bad favors apoptosis by
sequestering anti-apoptotic proteins (Bcl-2 and Bcl-xL) in the cyto-
plasm [33]. Our data indicate that DD1 treatment decreased levels
of phosphoSer136-Bad. By neutralizing anti-apoptotic proteins, Bad
could contribute to DD1's apoptotic effect. This observation strongly sug-
gests the involvement of the P70S6K/Bad pathway in DD1-mediated ap-
optosis in AML cells.
The pro-apoptotic protein Bax plays a central role in the
mitochondria-dependent apoptotic pathway [31]. Cytosolic Bax is inac-
tive due in part to its N-terminal domainwhich could have the ability to
lock the protein under an inactive conformation [46]. Following a death
signal, Bax is translocated to the outer mitochondrial membrane where
it promotes the release of apoptogenic factors including cytochrome c
[46]. The regulation of Bax translocation is related to conformational
changes that are under the control of different factors such as Bcl-2
and Bcl-xL [46]. The conformational changes of the N-terminal domain
of Bax could favor its mitochondrial translocation [46]. The monoclonal
antibody (mAb) targeted at residues 12–24 of human Bax, 6A7, detects
speciﬁcally the active form of Bax [47]. DD1 treatment induced Bax ac-
tivation (as shown with the 6A7 mAb), perturbed the mitochondrial
membrane and activated caspases -9 and -3 in U937 cells (indirectly,
since the drug does not stimulate caspase activities directly —
unpublished results, Piedfer et al.). In the extrinsic pathway, caspase-8
activation in turn leads directly to activation of caspase-3 and thus apo-
ptosis [30,48]. Moreover, once cleaved by caspase-8, truncated Bid can
migrate to the mitochondria where it can initiate the intrinsic pathway
and activate caspase-9 [32]. We provided evidence that DD1 treatment
induced caspase-8 activation, but not Bid truncation, in U937 cells. The
results of our caspase inhibition studies with the caspase inhibitors
argue strongly in favor of a key role for caspases -8, -9 and -3 in the ap-
optotic response to DD1. Taken as a whole, our data indicate that DD1
triggers apoptosis through both the intrinsic and extrinsic pathways.
Early studies suggested that P70S6K was involved in cisplatin-
mediated apoptosis in human lung cancer cells [49]. Cleavage of
P70S6K is observed in various epithelial cell lines in response to a
range of apoptotic stimuli (such as cisplatin, doxorubicin, TNF-α
and TRAIL) [37]. The biological signiﬁcance of caspase-3's role in
P70S6K degradation has recently been emphasized by the observation
of direct cleavage of P70S6K by human recombinant caspase-3
[37]. Accordingly, our study showed that the pan-caspase inhibitor
zVAD-fmk, the caspase-8 inhibitor zIETD-fmk (blocking caspase
8-mediated caspase-3 activation), the caspase-9 inhibitor zLEHD-fmk
(blocking caspase 9-mediated caspase-3 activation) and the caspase-3 in-
hibitor itself zDEVD-fmkprevented a decrease in P70S6K levels— thus in-
dicating that P70S6K protein downregulation is likely due to degradation
by caspase-3. We used K562 cells as a model of apoptosis-resistant cell
line [38] which express normal levels of caspases [50]. Our Western
blot experiments showed that P70S6K and active Bax proteins in K562
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however indicate that DD1 did not induce the apoptosis of K562 cells
and thiswas related to the lack of Bax activation and P70S6Kdegradation.
Our data strongly suggest that Bax induction and P70S6K cleavage are as-
sociated with DD1-induced apoptosis in AML cells.
K562 cells resist the proteasome inhibitor bortezomib by
overexpressing the proteasome'sβ5 subunit [38,51]. Cell death as a result
of proteasome inhibition involves Bax stimulation and caspase activation
[52,53]. These previous observations and our present data suggested that
DD1 has a role in inhibition of the proteasome. Firstly, we found that DD1
directly inhibited the chymotrypsin-like activity of the 20S proteasome
in vitro. Secondly, a combination of DD1 and bortezomib had additive,
pro-apoptotic effects on U937 cells. Thirdly, bortezomib-induced apo-
ptosis in U937 cells was also found to be associated with Bax activation
and P70S6K degradation. In accordance with our data, it was very re-
cently reported that bortezomib is capable of inducing dephosphoryla-
tion and downregulation of several proteins in the Akt/mTOR pathway
in cell lines representative of mantle cell lymphoma [54]. Finally, it is
not known whether there is a causal link between proteasome inhibi-
tion and P70S6K degradation. Recent data in HeLa cells fromLaussmann
et al. demonstrated that proteasome inhibition by bortezomib induces
the activation of caspase-8 independently of death ligands [55]. Thus,
one can legitimately hypothesize that DD1-mediated proteasome inhi-
bition leads ﬁrst to caspase-8 activation and then caspase-3 activation
leading to P70S6K degradation and Bad pro-apoptotic activity.
Bortezomibmanifests its anti-tumor activity viamultiplemechanisms
which include disruption of cell adhesion- and cytokine-dependent sur-
vival pathways (e.g. NF-κB signaling pathway), inhibition of angiogenesis
and suppression of PI3K/Akt/mTOR and MAPK pathways [52,56–59].
Moreover, bortezomib stimulates cytotoxicity through accumulation of
reactive oxygen species (ROS) [60,61]. Current evidence also supports a
critical role for upregulation and activation of BH3-only proteins in
mediating the proapoptotic action of bortezomib [52,56,62]. Indeed,
bortezomib has been shown to induce Bax (and Bak) conformation
change and to increase the expression of Noxa and Mcl-1 [52,63]. Ex-
pression of Noxa induced by bortezomib, is potentiated by the presence
of wild-type p-53, but occurs in a p53-independent manner [63]. Like
DD1, bortezomib has similar effects on leukemia cell lines and primary
AML cells i.e. anti-proliferative and pro-apoptotic activities [64–68] and
activation of caspases -8, -9 and -3 [69]. One study suggested that
proteasome inhibition by bortezomib affects the NF-κB pathway in pri-
mary leukemic stem cells [70]. Here, blocking NF-κB activity in the AML
cell line NB4 transfected with a dominant-negative mutant form of
Iκ-Bα that cannot be phosphorylated and degraded, did not prevent
the inhibitory effect of DD1 on cell growth and survival (Piedfer,
unpublished results). Our data therefore suggest that the mecha-
nism by which DD1 induces apoptosis of AML cells does not involve
the inhibition of NF-κB. It has also be noted that themajority of primary
AML cells sensitive in vitro to bortezomib showed immunophenotypic
features of the M4 and M5 subtypes [69]. In contrast, another recent
study showed that M1 blasts showed a higher proportion of apoptotic
cells than the M5 blasts [68]. Such discrepancy might be explained by
the culture conditions used in these studies. Here, we found that DD1
exhibits inhibitory effects on colony formation/survival of primary
AML cells independently of their FAB. While bortezomib exhibits clini-
cal efﬁcacy in multiple myeloma and mantle cell lymphoma, it appears
ineffective in AML [71–73]. Interestingly, a recent study has showed
that high basal levels of nuclear Nrf2 (a transcription factor that stimu-
lates protective anti-oxidant enzymes) in AML cells reduced ROS levels,
permitting AML cells to survive drug treatment [74]. The authors fur-
ther showed that Bach-1, a transcriptional repressor of a Nrf2, is rapidly
inactivated by bortezomib, allowing rapid induction of Nrf2-regulated
cytoprotective and detoxiﬁcation genes that protect AML cells from
bortezomib-induced apoptosis [74]. Whether the pro-apoptotic effect
of DD1 might be independent of Bach-1 inactivation remains to be
detailed.5. Conclusions
Our study emphasizes the concerted effects of DD1 on proteasome
inhibition and activation of caspase-dependent cascades (with P70S6K
degradation) in the in vitro induction of apoptosis in AML cells. Our
ﬁndings may provide a new experimental basis for AML therapy that
have to be conﬁrmed in vivo with murine models of AML [75] using
the xenotransplantation approaches [76,77]. The fact that bortezomib
induces drug resistance emphasizes the need for novel proteasome
inhibitors [78,79]. Of particular relevance with our study, some poly-
phenols including quercetin have been found to exhibit proteasome
inhibitory activity [80]. Proteasome inhibition by these polyphenols
seems to participate in overcoming multidrug resistance in tumors
[80]. Whether DD1, as novel proteasome inhibitor with properties
distinct from that of bortezomib, could serve as a chemosensitizer
will have to be evaluated. Finally, treatment with DD1 resulted in
antiproliferative and proapoptotic effects against other cancer cell lines
including T-ALL, myeloma and cervix adenocarcinoma, pointing to its
potential utility in other tumor types. In conclusion, the discovery of
DD1 as a novel proteasome inhibitor may have implications for disease
biology and treatment.
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